What recent research says about ibogaine
Scientific interest in ibogaine has surged in recent years — from clinical studies on veterans to policy decisions at the highest level. Here is what the evidence shows so far.
A policy push for research
In April 2026, President Trump signed an executive order accelerating psychedelic research for mental health — with ibogaine as the only substance named explicitly. The order directs $50 million through the ARPA-H program and calls on the FDA and DEA to create an access pathway for eligible patients (under Right to Try), alongside psilocybin and MDMA. Official fact sheet →
Studies published so far
88% less PTSD in veterans with brain injuries
In 30 special-forces veterans with traumatic brain injuries, a single dose of ibogaine (with IV magnesium) reduced PTSD symptoms by 88%, depression by 87%, and anxiety by 81% within a month. The WHO disability score dropped from 30.2 to 5.1, with no serious cardiac events. Source →
Signs of neural repair on scans
EEG and MRI analysis of the same cohort showed a reorganization of brain networks: increased theta rhythms in those with improved executive function, reduced hypervigilance, and signs of neural repair at the cortical level.
Release from opioid addiction
Observational studies from several international clinics report significant reductions in cravings and opioid withdrawal symptoms after ibogaine treatment, with some cases showing sustained abstinence for months after a single session. Source →
Reorganization of high-beta networks in PTSD
A recent analysis of high-beta brain connectivity in veterans with PTSD associates ibogaine with the reorganization of networks linked to hypervigilance — a possible neural mechanism behind symptom improvement. Source →
A new era for psychedelics
Ibogaine is part of a broader wave: psilocybin and MDMA are being studied intensively for PTSD and depression. After the FDA's rejection of MDMA in 2024, the new policy framework is relaunching funding and research in the field.
Safety under supervision
Ibogaine requires rigorous cardiac screening and administration under medical supervision. Modern protocols, including magnesium co-administration, significantly reduce the risks. That is why preparation and screening (interview, health questionnaire, recent ECG) are an essential part of any responsible retreat. See what the full preparation looks like →
More studies and updates on ibogaine are available at ibogaresearch.eu.